USD
+$0.00
(+0.00%
)At Close (As of Nov 28, 2025)
$313.21M
Market Cap
-
P/E Ratio
-1.44
EPS
$5.70
52 Week High
$3.80
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $187M |
| Total Revenue | $199M |
| Cost Of Revenue | $11M |
| Costof Goods And Services Sold | $11M |
| Operating Income | -$41M |
| Selling General And Administrative | $145M |
| Research And Development | $74M |
| Operating Expenses | $228M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $8.1M |
| Income Before Tax | -$23M |
| Income Tax Expense | -$4M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$19M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$41M |
| Ebitda | -$33M |
| Net Income | -$19M |
| Field | Value (USD) |
|---|---|
| Total Assets | $656M |
| Total Current Assets | $439M |
| Cash And Cash Equivalents At Carrying Value | $102M |
| Cash And Short Term Investments | $102M |
| Inventory | $1.7M |
| Current Net Receivables | $47M |
| Total Non Current Assets | $217M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $114M |
| Intangible Assets Excluding Goodwill | $114M |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $272M |
| Other Current Assets | $15M |
| Other Non Current Assets | - |
| Total Liabilities | $118M |
| Total Current Liabilities | $100M |
| Current Accounts Payable | $3.5M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $4.3M |
| Total Non Current Liabilities | $18M |
| Capital Lease Obligations | $12M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $12M |
| Other Current Liabilities | $92M |
| Other Non Current Liabilities | $9.6M |
| Total Shareholder Equity | $539M |
| Treasury Stock | - |
| Retained Earnings | -$174M |
| Common Stock | $58K |
| Common Stock Shares Outstanding | $58M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$16M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $8.1M |
| Capital Expenditures | $490K |
| Change In Receivables | - |
| Change In Inventory | -$29K |
| Profit Loss | - |
| Cashflow From Investment | -$17M |
| Cashflow From Financing | -$155K |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$19M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $187M |
| Total Revenue | $199M |
| Cost Of Revenue | $11M |
| Costof Goods And Services Sold | $11M |
| Operating Income | -$41M |
| Selling General And Administrative | $145M |
| Research And Development | $74M |
| Operating Expenses | $228M |
| Investment Income Net | - |
| Net Interest Income | - |
| Interest Income | - |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $8.1M |
| Income Before Tax | -$23M |
| Income Tax Expense | -$4M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$19M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$41M |
| Ebitda | -$33M |
| Net Income | -$19M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Vanda Pharmaceuticals Inc. is a biopharmaceutical company based in Washington, D.C., focused on developing and commercializing innovative therapies for significant unmet medical needs, particularly in central nervous system and sleep disorders. The company boasts a robust pipeline of products and a commitment to advancing patient care through scientific expertise and strategic focus on niche markets. Vanda's dedication to enhancing patient outcomes positions it as a key player in the biopharmaceutical industry, with potential for sustainable growth and impactful contributions to healthcare.